Bruker Corporation stands as a prominent global developer, manufacturer, and distributor of cutting-edge scientific instruments, alongside comprehensive analytical and diagnostic solutions. Its ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
$0.20 per share
Est. EPS $0.42 · Revenue $867.35M · 8 analysts
Est. EPS $0.90 · Revenue $1.03B · 7 analysts
Est. EPS $2.12 · Revenue $3.56B · 6 analysts
$0.20 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $3.4B | +2.1% | +1.8% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-8.6M | -107.6% | -461.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +45.9% | -6.3% | +4.9% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +6.9% | -8.7% | -242.5% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -0.3% | -107.4% | -454.6% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $13.9M | -89.8% | -326.0% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +0.4% | -90.0% | -321.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 83.2% | -34.0% | +17.0% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 1.73x | +7.9% | +19.0% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $6.2B | +7.5% | -1.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -0.15 vs 1.88 | -108.0% | -0.41 vs 0.42 | -197.7% |
| Revenue Surprise | $3.4B vs $3.4B | +0.4% | $838.5M vs $867.4M | -3.3% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Pusch Wolfgang | officer: President BMID Group | Common Stock | D | 3,473 | $56.90 |
| Aug 15, 2026 | Prause Burkhard | officer: PRES. & CEO, BRUKER BEST | Common Stock | A | 3,303 | — |
| Aug 15, 2026 | Prause Burkhard | officer: PRES. & CEO, BRUKER BEST | Stock Option (Right to Purchase) | A | 2,678 | $57.70 |
| Aug 15, 2026 | Pusch Wolfgang | officer: President BMID Group | Common Stock | A | 3,120 | — |
| Aug 15, 2026 | Pusch Wolfgang | officer: President BMID Group | Stock Option (Right to Purchase) | A | 2,529 | $57.70 |
Operator: Good day, and welcome to the Bruker Corporation Second Quarter 2026 Earnings Conference Call. [Operator Instructions]. Please note this event is being recorded. I would now like to hand the call over to Joe Kostka, Director of Investor Relations. Please go ahead. Joe Kostka: Good morning. I would like to welcome everyone to Bruker Corporation's Second Quarter 2026 Earnings Conference Call. My name is Joe Kostka, and I am the Director of Bruker Investor Relations. Joining me on today's call are our President and CEO, Frank Laukien; and our EVP and CFO, Gerald Herman. In addition to the earnings release we issued earlier today, during today's conference call, we will be referencing a slide presentation that can be downloaded from the Events and Presentations section of Bruker's Investor Relations website. During today's call, we will be highlighting non-GAAP financial information. Reconciliations of our non-GAAP to GAAP financial measures are included in our earnings release and are posted on our website at ir.bruker.com. Before we begin, I would like to reference Bruker's safe harbor statement, which is shown on Slide 2 of the presentation. During this conference call, we will or may make forward-looking statements regarding future events and the financial and operational performance of the company that involve risks and uncertainties, including those related to our recent acquisitions, geopolitical risks, wars or blockades, market demand, tariffs, currency exchange rates, competitive dynamics or supply chains. The company's actual results may differ materially from such statements. Factors that might cause such differences include, but are not limited to, those discussed in today's earnings release and in our Form 10-K for the period ending December 31, 2025, as updated by our other SEC filings, which are available on our website and on the SEC's website. Also, please note that the following information is based on current business conditions and on our outlook as of today, August 4, 2026. We do not intend to update our forward-looking statements based on new information, future events or for other reasons, except as may be required by law, prior to the release of our third quarter 2026 financial results expected in early November 2026. You should not rely on these forward-looking statements as necessarily representing our views or outlook as of any date after today. We will begin today's call with Frank providing an overview of our business progress. Gerald will then cover the financials for the second quarter of 2026 in more detail and comment on our full year 2026 financial outlook. Now I'd like to turn the call over to Bruker's CEO, Frank Laukien. Frank Laukien: Thanks, Joe. Good morning, everyone, and thank you for joining us on today's second quarter 2026 earnings call. We are pleased that Bruker has returned to organic revenue growth in the second quarter and that our focus on cost reductions and profitability improvements …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Frank H. Laukien | Chairman, Chief Executive Officer & President | USD 1,594,872 | — | 1960 | Active |
Mark R. Munch | Corporate Executive Vice President and President of Bruker Nano Group & Corporate | USD 1,119,503 | — | 1962 | Active |
Gerald N. Herman | Executive Vice President & Chief Financial Officer | USD 879,311 | Male | 1958 | Active |
Falko Busse | President of Bruker BioSpin Group | USD 822,109 | — | 1967 | Active |
Juergen Srega | President of Bruker Biosystems Group & Bruker Daltonics Division | USD 772,590 | Male | 1955 | Active |
Burkhard Prause | President and Chief Executive Officer of Bruker Energy & Supercon Technologies, Inc. | USD 595,963 | — | 1967 | Active |
Wolfgang Pusch | President of Bruker Microbiology & Infection Diagnostics Group | — | — | — | Active |
Thomas Bures | Chief Accounting Officer | — | Male | 1975 | Active |
J. Brent Alldredge | Senior Vice President, General Counsel, Secretary & Global Head of Compliance | — | Male | 1975 | Active |
[url="]Bruker Corporation[/url] (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced huma
LEIDEN, The Netherlands--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a majority investment in MIMETAS B.V., a developer of organ-on-a-chip platforms and advanced human tissue and disease models for drug discovery and development. The investment expands Bruker's post-genomic solutions for disease biology research, as well as for drug discovery and development into Microphysiological Systems (MPS), also referred to as New Approach Methodologies (NAMs), and based on human ph.
Bruker Corporation (BRKR) Q2 2026 Earnings Call Transcript
The Dow is up over 800 points after Monday's rally while upbeat earnings from Palantir (PLTR) is lifting tech and the broader market
The headline numbers for Bruker (BRKR) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
